ADMA Biologics is trading at $11.30 (+5.31%) in pre-market; the cause of the move remains unconfirmed.
- On October 15, the company announced peer-reviewed findings that its optimized IVIG process removed measured impurities while maintaining product quality and increasing yield.
- The report noted no associated thromboembolic events in postmarketing surveillance through July 2026. The company did not explicitly link the findings to the share-price move; no separate October 16 company announcement or clear broader-market catalyst was identified.